Better Therapeutics- Tradeable Rights - March 2021 Return on Equity

Better Therapeutics- Tradeable Rights - March 2021 (MCADR) currently reports a ROE of 317.73%. That is above the sector sector average of 11.73%. Use the charts on this page to explore Better Therapeutics- Tradeable Rights - March 2021's ROE history and peer comparisons.

Better Therapeutics- Tradeable Rights - March 2021's ROE of 317.73% is higher than the its sector sector average of 11.73%. That is roughly 2607.8% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Better Therapeutics- Tradeable Rights - March 2021's current 317.73% should be judged against industry norms (sector average: 11.73%) and against MCADR's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 317.73%, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is 11.73%. From there, open related valuation or income-statement pages for Better Therapeutics- Tradeable Rights - March 2021, and consider following MCADR for alerts when major investors trade the stock.